Skip to content

Ketamine: all studies

Page 373 of 449: studies 3,721 to 3,730 of 4,483, newest first. Back to the ketamine overview

Research

Mechanisms for anesthesia, unawareness, respiratory depression, memory replay and sleep: MHb > IPN > PAG + DRN + MRN > claustrum > cortical slow waves

arXiv Preprint Archive August 21, 2025 Karin Vadovičová preprint

My findings show what causes loss of awareness, anesthesia, memory replay, opioid induced respiratory depression (OIRD), and slow-wave sleep (SWS). Opiates are fast pain relievers and anesthetics that can cause respiratory arrest. I found how mu-opioids and anesthetics by activating medial habenula (MHb) and/or interpeduncular nucleus (IPN) induce unawareness and slowdown respiration. MHb...

Deconstructing the trip treatment: are hallucinogenic effects critical to the therapeutic benefits of psychedelics?

NPP Digit Psychiatry Neurosci August 20, 2025 Albert Garcia‐romeu 2 citations

Interest in “psychedelic therapies,” using substances such as ketamine, 3,4-methylenedioxymethamphetamine (MDMA), and psilocybin to treat psychiatric conditions, has grown steadily in recent years. Although pharmacologically distinct and functioning via differential mechanisms, these drugs are broadly classified as hallucinogenic, meaning they are thought to produce hallucinations. However,...

Endocannabinoids, depression, and treatment resistance: Perspectives on effective therapeutic interventions

Psychiatry Research August 18, 2025 Ilenia Rosa, L. Padula, Francesco Semeraro et al. 2 citations

Depression is a prevalent and heterogeneous disorder with significant personal and social consequences. The rise of treatment-resistant depression (TRD) challenges traditional approaches and underscores the need for a broader neurobiological perspective. When monoaminergic modulation proves insufficient, clinical guidelines increasingly turn to non-monoaminergic interventions such as...

DOI: 10.1016/j.psychres.2025.116697 (opens in new tab) Endocannabinoid system Depression economics Psychological intervention Resistance ecology +2

Interventional Psychiatry and Emerging Treatments for Posttraumatic Stress Disorder (PTSD): A Systematic Review.

Psychiatry and Clinical Psychopharmacology August 11, 2025 Reinhard Janssen-Aguilar, Shakila Meshkat, Huda Al-Shamali et al. 4 citations

Posttraumatic stress disorder (PTSD) is a severe, often difficult-to-treat condition, highlighting the need for innovative therapies. Interventional treatments, including neuromodulation, rapid-acting pharmacotherapies such as intravenous ketamine (IV-KET) and esketamine (ESK), and emerging psychedelic-assisted psychotherapies, offer promising solutions. This systematic review evaluates the...

Advances in the study of pharmacotherapy for addiction to naturally-derived psychoactive substances.

Chinese journal of natural medicines August 2025 Kexin Xie, Deli Xiao, Peng Xu et al.

Drug addiction, a disorder characterized by chronic relapse and compulsive drug use, poses a significant threat to public safety and human health. Addictive substances can be categorized as natural, semi-synthetic, or synthetic based on their origin. Additionally, they can be classified into three groups according to their pharmacological targets: opioids, hallucinogens, and cannabinoids that...

169. THERAPEUTIC MEMORY RECONSOLIDATION AS A TREATMENT FOR SUBSTANCE USE DISORDERS AND HOW PSYCHEDELICS ARE FACILITATING THIS INTERVENTION: THE UNITY STUDY

The International Journal of Neuropsychopharmacology August 1, 2025 S. Ofori, R. Das

Abstract Background Maladaptive motivational memory (MMM) is the term given to a learned association between environmental predictors of reward (cues) and the receipt of rewarding stimuli (reward). A key characteristic of MMMs is that they drive excessive consumption behaviours in a variety of disorders such as substance use disorders (SUDs) and behavioural addictions. MMMs underlie the...

577. CLINICAL EVIDENCE AND APPLICATIONS OF PSYCHEDELICS FOR MENTAL ILLNESSES

The International Journal of Neuropsychopharmacology August 1, 2025 Hiroe Tani

Abstract Background Psychedelics have long been explored as potential treatments for mental illnesses. Since the mid-20th century, clinical trials of psychedelics such as LSD for depression and anxiety in terminally ill patients have been conducted. In the 21st century, revived and accelerated efforts to promote the proper use of psychedelics in the medical field have led to increasingly...

426. THE MGLUR2/3 ANTAGONIST ENHANCES THE BEHAVIORAL AND CELLULAR ANTIDEPRESSANT-LIKE EFFECTS OF PSILOCYBIN AND SCOPOLAMINE

The International Journal of Neuropsychopharmacology August 1, 2025 Yana Babii, C. Barbara, Dorota Bederska‐łojewska et al.

Abstract Background Numerous data indicates that hallucinogens from various groups such as ketamine, scopolamine or psilocybin exert rapid antidepressant effects in both preclinical and clinical studies. Group II glutamate (mGlu) metabotropic receptor antagonists also show rapid antidepressant efficacy in animal studies, moreover we have shown that mGluR2/3 antagonist, LY341495 is able to...

The Future of Pain Management.

Neurologic Clinics August 1, 2025 Pravarakhya Puppalla, Tara Menon Pattilachan, Rodrigo Salmeron de Toledo Aguiar et al. 2 citations

This article explores the complexities of pain management, highlighting the multidimensional nature of pain, which encompasses affective, cognitive, and sensory experiences. The study examines the future of acute and chronic pain management through a thorough review of 3424 articles, ultimately including 143 relevant studies. Key findings indicate progress in treatment algorithms, novel...

DOI: 10.1016/j.ncl.2025.04.007 (opens in new tab) Full text (opens in new tab) Acute pain Chronic pain Pain intervention Pain management +10

Tusibí: Ni 2C-B ni “cocaína rosa”

Health and Addictions/Salud y Drogas July 29, 2025 Diego Fernández Piedra, Claudio Vidal Giné, Berta de la Vega Moreno 2 citations

El tusi o tusibí es una sustancia psicoactiva de composición variable que ha sido erróneamente asociada con la 2C-B y denominada “cocaína rosa” en discursos policiales y mediáticos. Su uso se ha expandido desde Colombia hacia América Latina, Europa y España, especialmente en contextos recreativos. Aunque la prevalencia general es baja, estudios realizados entre 2020 y 2024 muestran un notable...